• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Clovis Oncology Appoints Dr. Ronit Simantov to its Board of Directors

    7/12/21 4:05:00 PM ET
    $CLVS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $CLVS alert in real time by email

    Clovis Oncology, Inc. (NASDAQ:CLVS) announced today the appointment of Dr. Ronit Simantov to its Board of Directors, effective today.

    "I am very pleased to welcome Dr. Ronit Simantov to the Clovis Oncology Board of Directors, as she brings a wealth of expertise in oncology research and drug development to the role," said Patrick J. Mahaffy, President and CEO of Clovis Oncology. "Dr. Simantov's extensive background and experience will support Clovis' key strategic priorities as we continue to advance both Rubraca's pipeline into a potentially broader label and the Company's early-stage pipeline of targeted radiotherapy candidates, including FAP-2286, into clinical development."

    Dr. Simantov has served as chief medical officer of Gamida Cell Ltd. since July 2017. Prior to joining Gamida Cell, Dr. Simantov served as vice president, Oncology Global Medical Affairs at Pfizer Inc., where she was responsible for multiple oncology programs in various roles from 2011 to June 2017. Prior to Pfizer, Dr. Simantov served as vice president of clinical research at OSI Pharmaceuticals, as chief medical officer at CuraGen Corporation (acquired by Celldex) where she led development of small molecules and antibody-drug conjugates, and at Bayer HealthCare Pharmaceuticals, where she led the phase 3 study of Nexavar® (sorafenib) resulting in the first approval of a tyrosine kinase inhibitor in renal cell carcinoma. Prior to joining industry, Dr. Simantov spent seven years on the academic faculty at Weill Medical College of Cornell University, where she directed the fellowship program and conducted angiogenesis and vascular biology research. She has authored over 40 peer-reviewed manuscripts. Dr. Simantov holds an M.D. from New York University School of Medicine and a B.A. from Johns Hopkins University. She completed a residency in internal medicine at New York Hospital Cornell Medical Center, and a fellowship in hematology and oncology at Weill Cornell Medicine. We believe that Dr. Simantov possesses specific attributes that qualify her to serve on our board of directors, including her clinical development and research background in the field of oncology, as well as her expertise reflected in her academic experience and scientific and medical journal publications.

    About Clovis Oncology

    Clovis Oncology, Inc. is a biopharmaceutical company focused on acquiring, developing and commercializing innovative anti-cancer agents in the U.S., Europe and additional international markets. Clovis Oncology targets development programs at specific subsets of cancer populations, and simultaneously develops, with partners, for those indications that require them, diagnostic tools intended to direct a compound in development to the population that is most likely to benefit from its use. Clovis Oncology is headquartered in Boulder, Colorado, with additional office locations in the US and Europe. Please visit www.clovisoncology.com for more information.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20210712005776/en/

    Get the next $CLVS alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CLVS

    DatePrice TargetRatingAnalyst
    5/6/2022Buy → Neutral
    H.C. Wainwright
    9/21/2021$10.00 → $9.00Buy
    HC Wainwright & Co.
    8/5/2021$12.00 → $10.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $CLVS
    SEC Filings

    See more
    • SEC Form EFFECT filed by Clovis Oncology Inc.

      EFFECT - Clovis Oncology, Inc. (0001466301) (Filer)

      7/18/23 12:15:24 AM ET
      $CLVS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 15-12G filed by Clovis Oncology Inc.

      15-12G - Clovis Oncology, Inc. (0001466301) (Filer)

      7/11/23 12:09:55 PM ET
      $CLVS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form S-8 POS filed by Clovis Oncology Inc.

      S-8 POS - Clovis Oncology, Inc. (0001466301) (Filer)

      7/11/23 12:05:29 PM ET
      $CLVS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CLVS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Clovis Oncology downgraded by H.C. Wainwright

      H.C. Wainwright downgraded Clovis Oncology from Buy to Neutral

      5/6/22 11:33:29 AM ET
      $CLVS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • HC Wainwright & Co. reiterated coverage on Clovis Oncology with a new price target

      HC Wainwright & Co. reiterated coverage of Clovis Oncology with a rating of Buy and set a new price target of $9.00 from $10.00 previously

      9/21/21 6:26:42 AM ET
      $CLVS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • HC Wainwright & Co. reiterated coverage on Clovis Oncology with a new price target

      HC Wainwright & Co. reiterated coverage of Clovis Oncology with a rating of Buy and set a new price target of $10.00 from $12.00 previously

      8/5/21 6:07:39 AM ET
      $CLVS
      Biotechnology: Pharmaceutical Preparations
      Health Care